1
|
Pyrazolo[1,5-a][1,3,5]triazin-2-thioxo-4-ones derivatives as thymidine phosphorylase inhibitors: Structure, drug-like calculations and quantitative structure-activity relationships (QSAR) modeling. J Mol Struct 2020. [DOI: 10.1016/j.molstruc.2019.127027] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
2
|
Yamagami T, Kobayashi R, Moriyama N, Horiuchi H, Toyofuku E, Kadoh Y, Kawanishi E, Izumoto S, Hiramatsu H, Nanjo T, Sugino M, Utsugi M, Moritani Y. Scalable Process Design for a PDE10A Inhibitor Consisting of Pyrazolopyrimidine and Quinoxaline as Key Units. Org Process Res Dev 2019. [DOI: 10.1021/acs.oprd.9b00068] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Takafumi Yamagami
- Process Development Department, Production Technology & Supply Chain Management Division, Mitsubishi Tanabe Pharma Corporation, 3-16-89, Kashima, Yodogawa-ku, Osaka 532-8505, Japan
| | - Ryo Kobayashi
- Technology Management Department, Production Technology & Supply Chain Management Division, Mitsubishi Tanabe Pharma Corporation, 3-16-89, Kashima, Yodogawa-ku, Osaka 532-8505, Japan
| | - Noriaki Moriyama
- Technology Management Department, Production Technology & Supply Chain Management Division, Mitsubishi Tanabe Pharma Corporation, 3-16-89, Kashima, Yodogawa-ku, Osaka 532-8505, Japan
| | - Hideki Horiuchi
- Global Quality Assurance Department, Mitsubishi Tanabe Pharma Corporation, 3-16-89, Kashima, Yodogawa-ku, Osaka 532-8505, Japan
| | - Eiji Toyofuku
- Technology Management Department, Production Technology & Supply Chain Management Division, Mitsubishi Tanabe Pharma Corporation, 3-16-89, Kashima, Yodogawa-ku, Osaka 532-8505, Japan
| | - Yoichi Kadoh
- Research Unit/Immunology & Inflammation, Sohyaku Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, 1000, Kamoshida-cho, Aoba-ku, Yokohama 227-0033, Japan
| | - Eiji Kawanishi
- Research Unit/Frontier, Sohyaku Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, 2-2-50, Kawagishi, Toda-shi, Saitama 335-8505, Japan
| | - Shinichi Izumoto
- Analytical Research Department, Production Technology & Supply Chain Management Division, Mitsubishi Tanabe Pharma Corporation, 3-16-89, Kashima, Yodogawa-ku, Osaka 532-8505, Japan
| | - Hajime Hiramatsu
- Analytical Research Department, Production Technology & Supply Chain Management Division, Mitsubishi Tanabe Pharma Corporation, 3-16-89, Kashima, Yodogawa-ku, Osaka 532-8505, Japan
| | - Takehiro Nanjo
- Analytical Research Department, Production Technology & Supply Chain Management Division, Mitsubishi Tanabe Pharma Corporation, 3-16-89, Kashima, Yodogawa-ku, Osaka 532-8505, Japan
| | - Masuhiro Sugino
- Process Development Department, Production Technology & Supply Chain Management Division, Mitsubishi Tanabe Pharma Corporation, 3-16-89, Kashima, Yodogawa-ku, Osaka 532-8505, Japan
| | - Masayuki Utsugi
- Process Development Department, Production Technology & Supply Chain Management Division, Mitsubishi Tanabe Pharma Corporation, 3-16-89, Kashima, Yodogawa-ku, Osaka 532-8505, Japan
| | - Yasunori Moritani
- Process Development Department, Production Technology & Supply Chain Management Division, Mitsubishi Tanabe Pharma Corporation, 3-16-89, Kashima, Yodogawa-ku, Osaka 532-8505, Japan
| |
Collapse
|
3
|
Ivanova B, Spiteller M. Quinoxalines as potent selective CRFRs ligands for monitoring and brain diagnostic. Bioorg Chem 2014; 58:53-64. [PMID: 25437530 DOI: 10.1016/j.bioorg.2014.10.008] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2014] [Revised: 10/16/2014] [Accepted: 10/22/2014] [Indexed: 01/15/2023]
Abstract
The paper highlighted quinoxalines as potent ligands to corticotropin-releasing factor receptor types 1 and 2. The content includes design and structure-activity relationship of 50 model substances to CRFR1, CRFR2α and CRF2β, respectively. It is important to bear in mind, that our concept has based on challenging research task, designing for selective CRFRs ligands. Because,: (i) These macromolecules can bond more than one ligand, thus causing for a distinct physiological response; (ii) CRFRs also participate readily in protein-protein interactions; (iii) CRFRs have two step activation mechanism and; (iv) CRFR1 has low selectivity. In spite of, numerous research efforts, which have been devoted to the isolation of series peptidic and non-peptidic CRFRs agonists, the poor penetration across blood-brain barrier restricts, their wide application in the clinical practice. Furthermore, the biological role of CRFR2 is not yet fully understood. For that reason, the studies of the structure-activity relationship have significant impact in the field. The great advantages of quinoxalines as prospective ligands are based on their: (a) One-step synthetic road, using mild experimental conditions and, allowing to involve various functional groups in the molecular scaffold as well as good-to-excellent yields, employing Fischer and Hinsberg methods; (b) High selectivity to CRFRs sub-types and; (c) Tunable fluorescence emission within the frame of a large scale of the electromagnetic spectrum ∈ 500-700 nm.
Collapse
Affiliation(s)
- Bojidarka Ivanova
- Lehrstuhl für Analytische Chemie, Institut für Umweltforschung, Fakultät für Chemie, Universität Dortmund, Otto-Hahn-Straße 6, 44227 Dortmund, Nordrhein-Westfalen, Germany.
| | - Michael Spiteller
- Lehrstuhl für Analytische Chemie, Institut für Umweltforschung, Fakultät für Chemie, Universität Dortmund, Otto-Hahn-Straße 6, 44227 Dortmund, Nordrhein-Westfalen, Germany
| |
Collapse
|
4
|
Pesti JA, LaPorte T, Thornton JE, Spangler L, Buono F, Crispino G, Gibson F, Lobben P, Papaioannou CG. Commercial Synthesis of a Pyrrolotriazine–Fluoroindole Intermediate to Brivanib Alaninate: Process Development Directed toward Impurity Control. Org Process Res Dev 2013. [DOI: 10.1021/op400242j] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Jaan A. Pesti
- Early Phase Chemical Development, Bristol-Myers Squibb Company, New Brunswick, New Jersey 08923, United States
| | - Thomas LaPorte
- Early Phase Chemical Development, Bristol-Myers Squibb Company, New Brunswick, New Jersey 08923, United States
| | - John E. Thornton
- Early Phase Chemical Development, Bristol-Myers Squibb Company, New Brunswick, New Jersey 08923, United States
| | - Lori Spangler
- Early Phase Chemical Development, Bristol-Myers Squibb Company, New Brunswick, New Jersey 08923, United States
| | - Frederic Buono
- Early Phase Chemical Development, Bristol-Myers Squibb Company, New Brunswick, New Jersey 08923, United States
| | - Gerard Crispino
- Early Phase Chemical Development, Bristol-Myers Squibb Company, New Brunswick, New Jersey 08923, United States
| | - Frank Gibson
- Early Phase Chemical Development, Bristol-Myers Squibb Company, New Brunswick, New Jersey 08923, United States
| | - Paul Lobben
- Early Phase Chemical Development, Bristol-Myers Squibb Company, New Brunswick, New Jersey 08923, United States
| | - Christos G. Papaioannou
- Early Phase Chemical Development, Bristol-Myers Squibb Company, New Brunswick, New Jersey 08923, United States
| |
Collapse
|
5
|
Insuasty H, Insuasty B, Castro E, Quiroga J, Abonia R. An efficient two-step synthesis of novel 2-amino-substituted pyrazolo[1,5-a][1,3,5]triazines. Tetrahedron Lett 2013. [DOI: 10.1016/j.tetlet.2013.01.073] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
6
|
Pathirana C, Sfouggatakis C, Palaniswamy V. N-N migration of a carbamoyl group in a pyrazole derivative revealed by NMR. MAGNETIC RESONANCE IN CHEMISTRY : MRC 2013; 51:184-187. [PMID: 23338988 DOI: 10.1002/mrc.3921] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/06/2012] [Revised: 12/10/2012] [Accepted: 12/16/2012] [Indexed: 06/01/2023]
Abstract
During a synthesis of 5-amino-4-(6-methoxy-2-methylpyridin-3-yl)-3-methyl-1H-pyrazole-1-carboxamide (see Scheme 1), a side-reaction produced 3-amino-4-(6-methoxy-2-methylpyridin-3-yl)-5-methyl-1H-pyrazole-1-carboxamide as a by-product that forms an equilibrium with the target-compound. The structure of the by-product was elucidated by the interpretation of 1D and 2D (HMQC, HMBC) NMR data where (1)H-(15)N HMBC correlations revealed the position of carbamoyl group attachment on the pyrazole. Comparison of structures of the target-compound and the by-product showed that the latter resulted from N-N migration of the carbamoyl group in the target-compound.
Collapse
|
7
|
Badawy SI, Narang AS, LaMarche K, Subramanian G, Varia SA. Mechanistic basis for the effects of process parameters on quality attributes in high shear wet granulation. Int J Pharm 2012; 439:324-33. [DOI: 10.1016/j.ijpharm.2012.09.011] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2012] [Revised: 08/29/2012] [Accepted: 09/06/2012] [Indexed: 10/27/2022]
|
8
|
Zheng B, Conlon DA, Corbett RM, Chau M, Hsieh DM, Yeboah A, Hsieh D, Müslehiddinoğlu J, Gallagher WP, Simon JN, Burt J. Development of a Practical Synthesis of a Functionalized Pyrrolo[2,1-f][1,2,4]triazine Nucleus. Org Process Res Dev 2012. [DOI: 10.1021/op300252n] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Affiliation(s)
- Bin Zheng
- Chemical Development, Bristol-Myers Squibb Company, P.O. Box 191, New Brunswick, New Jersey 08903-0191,
United States
| | - David A. Conlon
- Chemical Development, Bristol-Myers Squibb Company, P.O. Box 191, New Brunswick, New Jersey 08903-0191,
United States
| | - R. Michael Corbett
- Chemical Development, Bristol-Myers Squibb Company, P.O. Box 191, New Brunswick, New Jersey 08903-0191,
United States
| | - Melissa Chau
- Chemical Development, Bristol-Myers Squibb Company, P.O. Box 191, New Brunswick, New Jersey 08903-0191,
United States
| | - Dau-Ming Hsieh
- Chemical Development, Bristol-Myers Squibb Company, P.O. Box 191, New Brunswick, New Jersey 08903-0191,
United States
| | - Agnes Yeboah
- Chemical Development, Bristol-Myers Squibb Company, P.O. Box 191, New Brunswick, New Jersey 08903-0191,
United States
| | - Daniel Hsieh
- Chemical Development, Bristol-Myers Squibb Company, P.O. Box 191, New Brunswick, New Jersey 08903-0191,
United States
| | - Jale Müslehiddinoğlu
- Chemical Development, Bristol-Myers Squibb Company, P.O. Box 191, New Brunswick, New Jersey 08903-0191,
United States
| | - William P. Gallagher
- Chemical Development, Bristol-Myers Squibb Company, P.O. Box 191, New Brunswick, New Jersey 08903-0191,
United States
| | - Jeffrey N. Simon
- Chemical Development, Bristol-Myers Squibb Company, P.O. Box 191, New Brunswick, New Jersey 08903-0191,
United States
| | - Justin Burt
- Chemical Development, Bristol-Myers Squibb Company, P.O. Box 191, New Brunswick, New Jersey 08903-0191,
United States
| |
Collapse
|
9
|
Three practical approaches for the synthesis of novel 4,7-dihetarylpyrazolo[1,5-a][1,3,5]triazines. Tetrahedron 2012. [DOI: 10.1016/j.tet.2012.09.029] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|